- Home
- SNTI vs NRXS Comparison
SNTI vs NRXS Comparison
Compare SNTI & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNTI | NRXS |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 44.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SNTI | NRXS |
|---|---|---|
| Price | $1.05 | $4.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.00 | $8.00 |
| AVG Volume (30 Days) | ★ 4.6M | 899.5K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | $150.00 | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $1.04 | $1.33 |
| 52 Week High | $5.10 | $6.20 |
Technical Indicators
Market Signals| Indicator | SNTI | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 30.78 | 75.47 |
| Support Level | $1.15 | $2.63 |
| Resistance Level | $1.28 | $4.70 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 1.19 | 90.68 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).